Dr. Steven B. Ketchum Net Worth

The estimated Net Worth of Steven B Ketchum is at least $6.34 Millón dollars as of 31 January 2024. Dr Ketchum owns over 79,500 units of Amarin Corp stock worth over $401,811 and over the last 16 years he sold AMRN stock worth over $5,181,098. In addition, he makes $758,137 as Pres of R&D y Sr. VP and Chief Scientific Officer at Amarin Corp.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Dr Ketchum AMRN stock SEC Form 4 insiders trading

Dr has made over 39 trades of the Amarin Corp stock since 2010, according to the Form 4 filled with the SEC. Most recently he exercised 79,500 units of AMRN stock worth $46,905 on 31 January 2024.

The largest trade he's ever made was selling 421,629 units of Amarin Corp stock on 27 January 2021 worth over $3,377,248. On average, Dr trades about 26,469 units every 83 days since 2008. As of 31 January 2024 he still owns at least 681,036 units of Amarin Corp stock.

You can see the complete history of Dr Ketchum stock trades at the bottom of the page.

Dr. Steven B. Ketchum biography

Dr. Steven B. Ketchum is the Pres of R&D, Sr. VP and Chief Scientific Officer at Amarin Corp.

What is the salary of Dr Ketchum?

As the Pres of R&D y Sr. VP and Chief Scientific Officer of Amarin Corp, the total compensation of Dr Ketchum at Amarin Corp is $758,137. There are 6 executives at Amarin Corp getting paid more, with John Thero having the highest compensation of $8,929,540.

How old is Dr Ketchum?

Dr Ketchum is 55, he's been the Pres of R&D y Sr. VP and Chief Scientific Officer of Amarin Corp since . There are 11 older and 5 younger executives at Amarin Corp. The oldest executive at Amarin Corp is Patrick O'Sullivan, 78, who is the Non-Executive Independent Director.

What's Dr Ketchum's mailing address?

Steven's mailing address filed with the SEC is C/O AMARIN PHARMA, INC., 440 US HIGHWAY 22, BRIDGEWATER, NJ, 08807.

Insiders trading at Amarin Corp

Over the last 13 years, insiders at Amarin Corp have traded over $25,876,836 worth of Amarin Corp stock and bought 581,426 units worth $751,974 . The most active insiders traders include John F Thero, Steven B Ketchum y David M Stack. On average, Amarin Corp executives and independent directors trade stock every 10 days with the average trade being worth of $29,442. The most recent stock trade was executed by Aaron Berg on 2 August 2024, trading 160,000 units of AMRN stock currently worth $102,400.

What does Amarin Corp do?

amarin corporation plc is a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health. amarin's product development program leverages its extensive experience in lipid science and the potential therapeutic benefits of polyunsaturated fatty acids. vascepa® (icosapent ethyl) is amarin's first fda approved product and is available in the united states by prescription. for more information about vascepa visit www.vascepa.com.

Complete history of Dr Ketchum stock trades at Amarin Corp y Sunesis Pharmaceuticals Inc

Amarin Corp executives and stock owners

Amarin Corp executives and other stock owners filed with the SEC include:

• John Thero,
  President, Chief Executive Officer, Director
• Stephen Ketchum,
  President - Research and Development, Senior Vice President, Chief Scientific Officer
• Joseph Kennedy,
  Executive Vice President, General Counsel, Secretary, Strategic Initiatives
• Aaron Berg,
  Senior Vice President, Chief Commercial Officer
• Michael Kalb,
  Chief Financial Officer, Senior Vice President, Assistant Secretary
• Joseph Zakrzewski,
  Non-Executive Independent Director
• Dr. Steven B. Ketchum Ph.D.,
  Pres of R&D, Exec. VP and Chief Scientific Officer
• Dr. Steven B. Ketchum,
  Pres of R&D, Sr. VP and Chief Scientific Officer
• Michael W. Kalb,
  CFO, Sr. VP & Assistant Sec.
• Aaron D. Berg,
  Exec. VP & Pres of U.S.
• Elisabeth Schwartz,
  IR Contact Officer
• Jan van Heek,
  Non-Executive Independent Director
• David Stack,
  Non-Executive Independent Director
• Kristine Peterson,
  Non-Executive Independent Director
• Patrick O'Sullivan,
  Non-Executive Independent Director
• Lars Ekman,
  Non-Executive Independent Chairman of the Board
• Alan J. Wills B.A., BA (Zoology), M.B.A., MBA,
  Exec. VP of Corp. Bus. Devel.
• Jason M. Marks J.D.,
  Chief Legal Officer & Corp. Sec.
• Karim Mikhail,
  Pres, CEO & Director
• Donna Pasek,
  Sr. VP of HR
• Rami Daoud,
  Sr. VP of Corp. Devel.
• Alina Kolomeyer,
  Director of Communications
• Daniel S. Dunham,
  Sr. VP & Chief Pharmaceutical Compliance Officer
• Healthcare Partners Ltd. Fo...,
  Director
• Louis Iii Sterling,
  
• Oliver O'connor,
  
• Paul Cohen,
  
• Kostas D Odysseas,
  
• Mark Di Paolo,
  
• Steven B Ketchum,
  Chief Scientific Officer
• Murray Stewart,
  
• Karim Mikhail,
  President and CEO
• Jason M. Marks,
  EVP,Chief Global Legal Officer
• Alfonso G Zulueta,
  
• Erin S. Enright,
  
• Thomas Charles Reilly,
  EVP and CFO
• Geraldine Murphy,
  
• Adam Mark Berger,
  
• Diane E. Sullivan,
  
• Olsen Per Wold,
  Director
• Keith Horn,
  
• Jonathan Provoost,
  EVP, Chief Legal Officer
• Patrice Eadon Bonfiglio,
  
• Patrick Holt,
  President and CEO